Core Insights - Pacira BioSciences has partnered with LG Chem to expand access to opioid-sparing postsurgical pain control in select Asia-Pacific markets through the exclusive commercialization of EXPAREL [1][2] Company Overview - Pacira BioSciences is focused on delivering innovative, non-opioid pain therapies, with three commercial-stage products: EXPAREL, ZILRETTA, and iovera® [3] - EXPAREL is a long-acting local analgesic approved for various postsurgical pain management techniques [3] - ZILRETTA is an extended-release injectable for osteoarthritis knee pain management [3] - Iovera® is a handheld device providing immediate, long-acting, drug-free pain control [3] - The company is advancing a pipeline of clinical-stage assets, including PCRX-201, a gene therapy for osteoarthritis of the knee in Phase 2 development [3] Partnership Details - LG Chem will have exclusive rights to commercialize EXPAREL in the designated territories, leveraging its experience in orthopedic pain management [2] - Pacira will receive an undisclosed upfront payment, a transfer price, and tiered royalties on future sales by LG Chem [2] - LG Chem is responsible for obtaining regulatory approvals in the licensed territories, with plans to file for marketing authorizations in South Korea and Thailand within six months [2]

Core Insights - Pacira BioSciences (PCRX) reported preliminary, unaudited total revenues of $196.9 million for Q4 2025, missing the Zacks Consensus Estimate of $199 million, leading to a 9.6% decline in stock price [1][5] Group 1: Product Revenues - Exparel's net product sales reached $155.8 million in Q4 2025, a 5% increase from the previous year, slightly exceeding the Zacks Consensus Estimate of $155 million [3][5] - Zilretta's net product sales were reported at $33 million, remaining flat year over year and missing the Zacks Consensus Estimate of $34.4 million [6][7] - Iovera's net product sales amounted to $7 million, an 8% increase from the year-ago quarter, but fell short of the Zacks Consensus Estimate of $7.3 million [8] Group 2: Annual Performance - For the full year 2025, Pacira BioSciences reported total revenues of $726.4 million, a 4% increase year over year, but below the Zacks Consensus Estimate of $728.8 million [9]

Market Performance - U.S. stocks showed positive movement, with the Nasdaq Composite gaining approximately 150 points on Friday [1] - The Dow increased by 0.38% to 49,453.05, while the NASDAQ rose by 0.66% to 23,635.11, and the S&P 500 climbed 0.48% to 6,954.85 [1] - European shares also experienced gains, with the eurozone's STOXX 600 up by 0.91% and other major indices like Spain's IBEX 35 and London's FTSE 100 also rising [6] - Asian markets closed mostly higher, with Japan's Nikkei 225 gaining 1.61% and China's Shanghai Composite rising 0.92% [7] Sector Performance - Utilities sector shares increased by 1.5% on Friday, while health care stocks saw a decline of 0.5% [1] Commodity Prices - Oil prices rose by 2.7% to $59.34, gold increased by 1.2% to $4,514.50, silver surged by 6.3% to $79.895, and copper rose by 2% to $5.9150 [5] Company News - Rich Sparkle Holdings Ltd shares surged 115% to $52.00 after signing a $39 million offering of 3 million ordinary shares at $13 per share [9] - Quanterix Corp shares increased by 31% to $8.54 following the appointment of a new CEO [9] - CG Oncology Inc shares rose by 24% to $52.18 after announcing an expedited timeline for clinical trial data [9] - Aquestive Therapeutics Inc shares dropped 40% to $3.72 due to FDA identified deficiencies [9] - Pacira Biosciences Inc shares fell 13% to $22.70 after reporting preliminary FY25 revenue results [9] - Beta Bionics Inc shares decreased by 31% to $21.98 following preliminary fourth-quarter financial results [9] Economic Indicators - Nonfarm payrolls increased by 50,000 in December, slightly below expectations [10] - The unemployment rate decreased to 4.4%, below expectations of 4.5% [10] - Average hourly earnings rose by 0.3%, matching forecasts [10] - Housing starts declined by 4.6% to an annualized rate of 1.246 million units [10] - Building permits fell by 0.2% to an annualized rate of 1.412 million [10] - The University of Michigan's consumer sentiment index rose to 54.0, the highest since September 2025 [2][10]

Market Performance - U.S. stocks showed positive movement, with the Nasdaq Composite gaining approximately 150 points on Friday [1] - The Dow increased by 0.38% to 49,453.05, while the NASDAQ rose by 0.66% to 23,635.11, and the S&P 500 climbed 0.48% to 6,954.85 [1] - Utilities sector shares increased by 1.5%, while health care stocks experienced a decline of 0.5% [1] Commodity Prices - Oil prices rose by 2.7% to $59.34, gold increased by 1.2% to $4,514.50, silver surged by 6.3% to $79.895, and copper rose by 2% to $5.9150 [5] European Market Trends - European shares were generally higher, with the eurozone's STOXX 600 gaining 0.91%, Spain's IBEX 35 Index rising 0.01%, London's FTSE 100 increasing by 0.85%, Germany's DAX up by 0.43%, and France's CAC 40 rising by 1.23% [6] Asian Market Trends - Asian markets closed mostly higher, with Japan's Nikkei 225 gaining 1.61%, Hong Kong's Hang Seng Index up by 0.32%, China's Shanghai Composite rising by 0.92%, while India's BSE Sensex fell by 0.72% [7] Company-Specific Movements - Rich Sparkle Holdings Ltd saw its shares increase by 115% to $52.00 after signing a $39 million offering of 3 million ordinary shares at $13 per share [9] - Quanterix Corp shares surged by 31% to $8.54 following the appointment of Everett Cunningham as President and CEO [9] - CG Oncology Inc shares rose by 24% to $52.18 after announcing an expedited timeline for clinical trial data [9] - Aquestive Therapeutics Inc shares dropped by 40% to $3.72 due to an FDA letter identifying deficiencies [9] - Pacira Biosciences Inc shares fell by 13% to $22.70 after reporting preliminary FY25 revenue results [9] - Beta Bionics Inc shares decreased by 31% to $21.98 following preliminary fourth-quarter financial results [9] Economic Indicators - Nonfarm payrolls increased by 50,000 in December, slightly below expectations of 60,000 [10] - The unemployment rate decreased from 4.5% in November to 4.4%, below expectations [10] - Average hourly earnings rose by 0.3%, matching forecasts [10] - Housing starts declined by 4.6% to an annualized rate of 1.246 million units, while building permits fell by 0.2% to an annualized rate of 1.412 million [10] - The University of Michigan's consumer sentiment index rose to 54.0 in January, the highest since September 2025 [10]

Financial Performance - Preliminary unaudited total revenue for 2025 was $726.4 million, up from $701.0 million in 2024, representing a year-over-year increase of approximately 3.5%[1] - Full-year EXPAREL net product sales reached $575.1 million in 2025, compared to $549.0 million in 2024, reflecting a volume growth of 6%[4] - Fourth quarter EXPAREL net product sales were $155.8 million, an increase from $147.7 million in the same quarter of 2024, marking a volume growth of 7%[5] - Full-year ZILRETTA net product sales were $116.6 million in 2025, down from $118.1 million in 2024[12] - Full-year iovera° net product sales increased to $24.2 million in 2025, compared to $22.8 million in 2024[12] Share Repurchase and Cost Management - The company repurchased 2.0 million shares of common stock for $50.0 million during the fourth quarter, with $150.0 million remaining on its share repurchase authorization[7] - The company anticipates a reduction in force by July 2025, which is expected to yield cost savings[30] Strategic Initiatives - Pacira's strategic priorities, termed '5x30', focus on sustainable long-term growth and operational progress[2] - The company is focused on the commercialization of EXPAREL, ZILRETTA, and iovera°, with plans to expand their use to additional indications[32] - The success of EXPAREL, ZILRETTA, and iovera° is contingent on the timing and success of FDA supplemental New Drug Applications and EMA Marketing Authorization Applications[32] - The company is evaluating and developing additional product candidates utilizing proprietary multivesicular liposome (pMVL) drug delivery technology[32] Pipeline Development - The company is advancing its pipeline with PCRX-201, a gene therapy for knee osteoarthritis, currently in Phase 2 clinical development[26] - The company has identified numerous cytokines for potential locally administered genetic therapies using its high-capacity adenovirus vector platform[29] Gene Therapy Technology - The HCAd vector is significantly more efficient at delivering genes into cells compared to AAV vectors, allowing for effective treatment with smaller doses[31] - The HCAd platform can carry up to 30,000 base pairs of DNA, enabling gene therapy for multiple or larger genes[31] - Genetic medicines based on the HCAd platform can be administered locally and allow for potential redosing at therapeutically appropriate intervals[31] - The efficient delivery of genes means that thousands of doses can be produced in a single batch, leading to a commercially attractive cost of goods profile[31] Future Outlook and Risks - Pacira expects to report complete financial results for the fourth quarter and full-year 2025 in the first quarter of 2026[6] - Future growth potential and financial results are subject to various risks, including integration challenges from the acquisition of GQ Bio Therapeutics GmbH[30] - Actual results may differ materially from forward-looking statements due to known and unknown risks and uncertainties[33]

Core Insights - Pacira BioSciences reported record-high total revenue of $726.4 million for the year ended December 31, 2025, representing an increase from $701.0 million in 2024, driven by strong sales of EXPAREL and share repurchase activities [1][4][6] Revenue Highlights - Fourth quarter EXPAREL net product sales reached $155.8 million in 2025, up from $147.7 million in 2024, with a volume growth of 7 percent [8] - Full-year EXPAREL net product sales were $575.1 million in 2025, compared to $549.0 million in 2024, reflecting a 6 percent volume growth [8] - Fourth quarter ZILRETTA net product sales were $33.0 million in 2025, slightly down from $33.1 million in 2024 [8] - Fourth quarter iovera° net product sales increased to $7.0 million in 2025 from $6.5 million in 2024 [8] - Other revenue, including sales of bupivacaine liposome injectable suspension, was $1.1 million in the fourth quarter of 2025, compared to zero in the same period of 2024 [8] Share Repurchase Program - During the fourth quarter of 2025, the company repurchased 2.0 million shares of its common stock for $50.0 million, with $150.0 million remaining on its current share repurchase authorization [6] Strategic Outlook - The CEO emphasized the company's solid execution and progress in advancing its strategic priorities, positioning it for sustainable long-term success and significant revenue growth moving forward [2]

Core Insights - Pacira BioSciences, Inc. is committed to delivering innovative, non-opioid pain therapies to transform patients' lives [1][2] - The company will present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026, at 11:15 AM PST [1] Company Overview - Pacira has three commercial-stage non-opioid treatments: - EXPAREL, a long-acting local analgesic approved for various postsurgical pain management techniques [2] - ZILRETTA, an extended-release injectable for osteoarthritis knee pain management [2] - iovera®, a handheld device providing immediate, long-acting, drug-free pain control [2] - The company is advancing a pipeline of clinical-stage assets, including PCRX-201, a novel gene therapy in Phase 2 development for knee osteoarthritis [2]

Group 1 - DOMA Perpetual Capital Management owns approximately 6.83% of the outstanding shares of Pacira BioSciences (PCRX) and intends to nominate three independent director candidates at the Company's 2026 annual meeting of stockholders [1] - DOMA asserts that the Company's Board of Directors should pursue an immediate sale of the Company [1] - DOMA criticizes the current level of Executive Compensation and General Spending as exorbitant and unmerited, questioning the Board's fiduciary oversight [1]

Core Insights - Pacira Biosciences has joined the PROBE Consortium to enhance osteoarthritis research and patient care globally, leveraging data from over 70 million individuals [1][3] - The initiative aims to address significant unmet needs in osteoarthritis treatment, particularly due to a lack of innovation since the introduction of ZILRETTA [2][3] Company Overview - Pacira specializes in innovative, non-opioid pain therapies, with three commercial-stage products: EXPAREL, ZILRETTA, and iovera [4] - ZILRETTA is the first and only extended-release intra-articular therapy approved for osteoarthritis knee pain, providing pain relief for up to 16 weeks [5] PROBE Consortium Objectives - The PROBE initiative includes 38 partners from various sectors, aiming to transform osteoarthritis diagnosis and treatment through improved data analysis and trial designs [3][7] - Key strategies include creating a regulation-compliant database network, utilizing AI for disease progression predictions, and developing novel trial endpoints [7]

Industry Overview - The biotech industry has shown strong performance in 2025 despite a challenging macroeconomic environment, driven by new drug approvals and pipeline progress [1] - Mergers and acquisitions (M&A) surged in 2025, with large pharmaceutical and biotech companies expanding their portfolios through strategic collaborations and acquisitions [2] - The Zacks Biomedical and Genetics industry has outperformed both the Zacks Medical sector and the S&P 500, gaining 22.1% in the last six months compared to 12.5% and 16.5% respectively [18] Key Trends - Innovation and execution are critical, with a focus on high-profile drugs and innovative pipeline development, particularly with the rise of AI technology in drug discovery [6] - Successful commercialization is essential for drug uptake, often requiring collaborations with larger firms due to funding and expertise limitations of smaller biotechs [7] - Pipeline setbacks and potential tariffs pose challenges, as drug development is costly and time-consuming, with many drugs taking years to gain regulatory approval [13][14] Notable Companies - Amicus Therapeutics (FOLD) has performed well, with its lead drug Galafold showing strong demand and recent FDA approval for Pombiliti + Opfolda boosting its portfolio [24] - ANI Pharmaceuticals (ANIP) has seen significant growth in its rare disease franchise, with sales of its ACTH-based injection Cortrophin Gel surging 70% year-over-year [28] - Arcutis Biotherapeutics (ARQT) is focused on treating inflammatory skin diseases, with its lead product Zoryve performing well and expanding its label [32] - Tango Therapeutics is developing precision medicine for oncology, with promising data from its ongoing studies [36] - Pacira BioSciences (PCRX) maintains momentum with its lead drug Exparel and is looking to expand its label further [38]